1-20 of 112
Talha Munir
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

A matching-adjusted indirect comparison (MAIC) of zanubrutinib vs venetoclax + ibrutinib in treatment-naive chronic lymphocytic leukemia (CLL)

Free
Talha Munir, Leyla Mohseninejad, Sheng Xu, Keri Yang, Rhys Williams, Remus Vezan, Nicolas Martinez-Calle
Journal: Blood
Blood (2025) 146 (Supplement 1): 7436.
https://doi.org/10.1182/blood-2025-7436
Published: 2025
Journal Articles

MRD-guided ibrutinib plus venetoclax improves outcomes in CLL patients with TP53, ATM, or NOTCH1 aberrations compared to ibrutinib and FCR: Results from the Phase III NCRI FLAIR trial

Free
Surita Dalal, Jane Shingles, Sean Girvan, David Cairns, Paul Glover, Helen Warren, Thomas Grand, Nichola Webster, Andy Rawstron, Darren Newton, Charlotte Evans, Ruth de Tute, Anna Hockaday, Sharon Jackson, Sue Bell, Natasha Greatorex, David Stones, David Allsup, Adrian Bloor, Anita Sarma, Abraham Mullasseril Varghese, Peter Hillmen, Talha Munir
Journal: Blood
Blood (2025) 146 (Supplement 1): 679.
https://doi.org/10.1182/blood-2025-679
Published: 2025
Journal Articles

Pirtobrutinib in Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL): Final update from the Phase 1/2 BRUIN study

Free
Michael Wang, Jonathon Cohen, Nirav Shah, Wojciech Jurczak, Pier Luigi Zinzani, Chan Cheah, Chaitra Ujjani, Youngil Koh, Won Seog Kim, Sunita Dwivedy Nasta, Ian Flinn, Benoit Tessoulin, Shuo Ma, Alvaro Alencar, David Lewis, Jennifer Woyach, Kami Maddocks, Krish Patel, Yucai Wang, Joanna Rhodes, Constantine Tam, John Seymour, Hirokazu Nagai, Julie Vose, Bita Fakhri, Marc Hoffmann, Francisco Hernandez-Ilizaliturri, Andrew Zelenetz, Anita Kumar, Talha Munir, Donald Tsai, Paolo Abada, Minna Balbas, Jian Li, Ying (denise) Wang, Lindsey Roeker, Toby Eyre
Journal: Blood
Blood (2025) 146 (Supplement 1): 665.
https://doi.org/10.1182/blood-2025-665
Published: 2025
Journal Articles

Optimising MRD-guided treatment: UMRD4 as a half-way treatment timepoint for ibrutinib-venetoclax substantially delays MRD relapse after end of treatment in both IGHV-mutated and IGHV-unmutated CLL.

Free
Andy Rawstron, David Cairns, Nichola Webster, Surita Dalal, Jane Shingles, Ruth de Tute, Anna Hockaday, Sharon Jackson, Sue Bell, Natasha Greatorex, David Stones, David Allsup, Adrian Bloor, Anita Sarma, Abraham Mullasseril Varghese, Talha Munir, Peter Hillmen
Journal: Blood
Blood (2025) 146 (Supplement 1): 794.
https://doi.org/10.1182/blood-2025-794
Published: 2025
Journal Articles

Pirtobrutinib in Relapsed/Refractory (R/R) Waldenström macroglobulinemia (WM): Up to 5 years of follow-up from the Phase 1/2 BRUIN study

Free
Chan Cheah, Manish Patel, Toby Eyre, Wojciech Jurczak, David Lewis, Thomas Gastinne, Shuo Ma, Jonathon Cohen, Krish Patel, Jennifer Brown, Lydia Scarfo, Talha Munir, Ewa Lech-Maranda, Marc Hoffmann, Chaitra Ujjani, Bita Fakhri, Michael Wang, Koji Izutsu, Hirokazu Nagai, Constantine Tam, Joanna Rhodes, Julie Vose, Matthew McKinney, James Gerson, Minal Barve, Bryone Kuss, Youngil Koh, Aisling Barrett, Steven Treon, Jorge Castillo, John Seymour, Amy Ruppert Stark, Samuel McNeely, Richard Walgren, Donald Tsai, Katherine Bao, Binoj Chandrasekharan Nair, Jennifer Woyach, Lia Palomba
Journal: Blood
Blood (2025) 146 (Supplement 1): 226.
https://doi.org/10.1182/blood-2025-226
Published: 2025
Journal Articles

Sustained efficacy of zanubrutinib (zanu) vs bendamustine + rituximab (BR) in treatment (tx)-naive chronic lymphocytic leukemia/small lymphocytic lymphoma (TN SLL/CLL) and continued favorable survival in non-randomized patients (pts) with del(17p): 6-year follow-up in the phase 3 SEQUOIA study

Free
Constantine Tam, Talha Munir, Tadeusz Robak, Jennifer Brown, Brad Kahl, Paolo Ghia, Stephen Opat, Patricia Walker, Masa Lasica, Ian Flinn, Jiayi Shen, Nataliya Kuptsova-Clarkson, Marcus Lefebure, Jamie Hirata, Wojciech Jurczak, Mazyar Shadman
Journal: Blood
Blood (2025) 146 (Supplement 1): 2129.
https://doi.org/10.1182/blood-2025-2129
Published: 2025
Journal Articles

Ibrutinib plus rituximab leads to superior progression-free and overall survival to FCR in previously untreated CLL: Results of the Phase III NCRI FLAIR trial

Free
Talha Munir, Sean Girvan, Annah Muli, David Cairns, David Allsup, Adrian Bloor, Abraham Mullasseril Varghese, Angus Broom, Moya Young, Ben Kennedy, Renata Walewska, Michelle Furtado, Gavin Preston, Jeffrey Neilson, Nicholas Pemberton, Gamal Sidra, Nick Morley, Kate Cwynarski, Toby Eyre, Francesco Forconi, Simona Gatto, Shankara Paneesha, Christopher Fox, Dena Howard, Anna Hockaday, Julia Brown, Sharon Jackson, David Stones, Sue Bell, Natasha Greatorex, Nichola Webster, Jane Shingles, Surita Dalal, Piers Patten, Andy Rawstron, Peter Hillmen
Journal: Blood
Blood (2025) 146 (Supplement 1): 2128.
https://doi.org/10.1182/blood-2025-2128
Published: 2025
Journal Articles

Pirtobrutinib in post-cbtki CLL/SLL: Final update from the Phase 1/2 BRUIN study with more than 5 years follow-up

Free
William Wierda, Jennifer Brown, Paolo Ghia, Lindsey Roeker, Krish Patel, Toby Eyre, Talha Munir, Ewa Lech-Maranda, Nicole Lamanna, Constantine Tam, John Seymour, Benoit Tessoulin, Nirav Shah, Chaitra Ujjani, Bita Fakhri, Catherine Coombs, Ian Flinn, Manish Patel, Sunita Dwivedy Nasta, Jonathon Cohen, Alvaro Alencar, Chan Cheah, Shuo Ma, Joanna Rhodes, Deepa Jagadeesh, Pier Luigi Zinzani, Anders Österborg, Koji Izutsu, Noriko Fukuhara, Donald Tsai, Paolo Abada, Minna Balbas, Jian Li, Ying (denise) Wang, Wojciech Jurczak, Jennifer Woyach
Journal: Blood
Blood (2025) 146 (Supplement 1): 2115.
https://doi.org/10.1182/blood-2025-2115
Published: 2025
Journal Articles

Bexobrutideg (NX-5948), a novel Bruton's tyrosine kinase (BTK) degrader, shows high clinical activity and tolerable safety in patients with Waldenström macroglobulinemia: Updated results from an ongoing Phase 1a/b study

Free
Nirav Shah, Scott Huntington, David Lewis, Talha Munir, Graham Collins, Alvaro Alencar, Kim Linton, Zulfa Omer, Dima El-Sharkawi, Mary Gleeson, Pamela McKay, Jeanette Doorduijn, Jeffery Smith, Daniel Morillo, Pau Abrisqueta, Sarah Injac, Astrid Pulles
Journal: Blood
Blood (2025) 146 (Supplement 1): 5359.
https://doi.org/10.1182/blood-2025-5359
Published: 2025
Journal Articles

CaDAnCe-302, a phase 3, open-label, randomized study of BGB-16673 compared with idelalisib + rituximab (R), bendamustine + R, or venetoclax + R re-treatment in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma previously exposed to both a BTK and BCL2 inhibitor

Free
Constantine Tam, John Seymour, Jiayi Shen, Jan Michel, Maryam Sarraf Yazdy, Patrick Brown, Shelonitda Rose, Motohisa Takai, Meghan Thompson, Mark-David Levin, Talha Munir, Paolo Ghia, Jeff Sharman
Journal: Blood
Blood (2025) 146 (Supplement 1): 8245.
https://doi.org/10.1182/blood-2025-8245
Published: 2025
Journal Articles

The effect of breakthrough hemolysis on complement factor h and factor I levels in paroxysmal nocturnal hemoglobinuria

Free
Matthew Holt, Daniel Payne, Natalie Fox, Claire McKinley, Morag Griffin, Petra Muus, Talha Munir, Alexandra Pike, Louise Arnold, Sateesh Nagumantry, Richard Kelly, Darren Newton
Journal: Blood
Blood (2025) 146 (Supplement 1): 3193.
https://doi.org/10.1182/blood-2025-3193
Published: 2025
Journal Articles

Spontaneous remissions in paroxysmal nocturnal hemoglobinuria: True remission or clonal evolution to malignancy?

Free
Caitlin Roger, Matthew Holt, Louise Arnold, Lindsay Mitchell, Sateesh Nagumantry, Katharine Lowndes, Alexandra Pike, Talha Munir, Petra Muus, Morag Griffin, Richard Kelly
Journal: Blood
Blood (2025) 146 (Supplement 1): 29.
https://doi.org/10.1182/blood-2025-29
Published: 2025
Journal Articles

Real-world use of oral iptacopan monotherapy in paroxysmal nocturnal hemoglobinuria

Free
Matthew Holt, Richard Kelly, Regis Peffault De Latour, Morag Griffin, Shreyans Gandhi, Edouard Forcade, Francesco Versino, Roochi Trikha, Alexandra Pike, Joanna Large, Michael Loschi, Marc Michel, Petra Muus, Talha Munir, Alice Garnier, Simona Pagliuca, Yosr Hicheri, Isabelle Brindel, Sateesh Nagumantry, Lynda Maafa, Louise Arnold, Austin Kulasekararaj, Flore Sicre-de-Fontbrune
Journal: Blood
Blood (2025) 146 (Supplement 1): 1427.
https://doi.org/10.1182/blood-2025-1427
Published: 2025
Journal Articles

Integrating patient and clinician perspectives to advance R/R CLL care: Results of a multi-pronged global initiative

Free
Carmine Deluca, Michael Beyer, Marina Wanes, Jessica Massey, Meghan Thompson, Talha Munir, Wojciech Jurczak, Brian Koffman
Journal: Blood
Blood (2025) 146 (Supplement 1): 6428.
https://doi.org/10.1182/blood-2025-6428
Published: 2025
Journal Articles

Acquired Bruton's tyrosine kinase mutations in patients treated on the ibrutinib and rituximab, ibrutinib alone, and ibrutinib and venetoclax arms of the national multi-centre Phase III FLAIR study in previously untreated CLL patients

Free
Charlotte Evans, Surita Dalal, Darren Newton, Jennifer Carter, Nichola Webster, Andy Rawstron, Ruth de Tute, Anna Hockaday, Sharon Jackson, Sue Bell, Natasha Greatorex, David Stones, David Allsup, Adrian Bloor, Anita Sarma, Abraham Mullasseril Varghese, Peter Hillmen, Talha Munir
Journal: Blood
Blood (2025) 146 (Supplement 1): 796.
https://doi.org/10.1182/blood-2025-796
Published: 2025
Journal Articles

Bexobrutideg (NX-5948), a novel Bruton's tyrosine kinase (BTK) degrader, demonstrates rapid and durable clinical responses in Relapsed/Refractory chronic lymphocytic leukemia (CLL): New and updated findings from an ongoing Phase 1a/b trial

Free
Zulfa Omer, Alexey Danilov, Francesco Forconi, Talha Munir, Mary Gleeson, Nirav Shah, Graham Collins, Alvaro Alencar, Jane Robertson, Jonathon Cohen, Karan Dixit, Danielle Brander, John Byrd, Allison Winter, Jeffery Smith, Dima El-Sharkawi, Michal Kwiatek, Iwona Hus, Prioty Islam, Sebastian Grosicki, Michael Tees, Thorsten Zenz, Joanna Romejko-Jarosinska, Sarah Injac, Wojciech Jurczak
Journal: Blood
Blood (2025) 146 (Supplement 1): 86.
https://doi.org/10.1182/blood-2025-86
Published: 2025
Journal Articles

Number of cardiac deaths associated with ibrutinib versus zanubrutinib for the treatment of chronic lymphocytic leukemia: A European risk-based estimation

Free
Talha Munir, Paolo Sportoletti, Andrea Visentin, Leyla Mohseninejad, Lianne Barnieh, Keri Yang, Wassim Aldairy, Sheila Mpima, Vicky Casey, Rhys Williams, Raul Diez Fernandez, Francisco Javier Diaz Galvez, Vincent Levy
Journal: Blood
Blood (2025) 146 (Supplement 1): 8033.
https://doi.org/10.1182/blood-2025-8033
Published: 2025
Journal Articles

Number of patients needed to treat to prevent one atrial fibrillation event with zanubrutinib versus ibrutinib and acalabrutinib in B-cell malignancies

Free
Talha Munir, Paolo Sportoletti, Leyla Mohseninejad, Lianne Barnieh, Tushar Srivastava, Kate Ren, Wassim Aldairy, Ayad Ali, Keri Yang, Rhys Williams, Joe-Elie Salem
Journal: Blood
Blood (2025) 146 (Supplement 1): 8024.
https://doi.org/10.1182/blood-2025-8024
Published: 2025
Journal Articles

CaDAnCe-304, a phase 3, open-label, randomized study to evaluate the safety and efficacy of Bruton tyrosine kinase degrader BGB-16673 compared with pirtobrutinib in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma

Free
Meghan Thompson, Constantine Tam, Kenneth Wu, Sheel Patel, Motohisa Takai, Patrick Phuong, Shelonitda Rose, Mark-David Levin, Talha Munir, Paolo Ghia, John Seymour
Journal: Blood
Blood (2025) 146 (Supplement 1): 5691.
https://doi.org/10.1182/blood-2025-5691
Published: 2025
Journal Articles

Switching between complement inhibitors in patients with PNH: A real-world analysis of strategy, efficacy, and safety.

Free
Morag Griffin, Bruno Fattizzo, Jong Wook Lee, Richard Kelly, Roochi Trikha, Yasutaka Ueda, Jun-ichi Nishimura, Christopher Patriquin, Alexander Röth, Petra Muus, Jens Panse, Miguel Gómez Álvarez, Alexandra Pike, Talha Munir, Shreyans Gandhi, Austin Kulasekararaj
Journal: Blood
Blood (2025) 146 (Supplement 1): 1114.
https://doi.org/10.1182/blood-2025-1114
Published: 2025